Research programme: tumour necrosis factor/interleukin 6 inhibitor - Bone Medical

Drug Profile

Research programme: tumour necrosis factor/interleukin 6 inhibitor - Bone Medical

Alternative Names: BN 006

Latest Information Update: 26 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bone Medical
  • Developer Bone Medical; Institute of Bone & Joint Research; William Harvey Research Institute
  • Class Antirheumatics; Peptides
  • Mechanism of Action Interleukin 6 inhibitors; Macrophage inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Rheumatoid arthritis

Most Recent Events

  • 28 Jan 2013 Pharmacodynamics data from a preclinical study in Rheumatoid arthritis released by Bone Medical
  • 01 Mar 2011 Preclinical development is ongoing
  • 21 Dec 2004 Preclinical trials in Rheumatoid arthritis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top